No-Needle blood draw device tested in ER to cut contamination

NCT ID NCT07348289

Recruiting now Knowledge-focused Sponsor: Intermountain Health Care, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a needle-free device called PIVO that draws blood through an existing IV line in the emergency department. Researchers want to see if using this device reduces contamination of blood cultures and lowers the number of needle sticks for patients. Up to 10,000 patients will be included, and staff will be trained on how to use the device. The main goals are to measure how often the device is used and whether it leads to cleaner blood samples.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PIVO device (needle-free blood draw device)
What this could lead to: If successful, this could make blood culture collection safer and more comfortable for patients by reducing needle sticks and contamination.
What could go wrong: This is an observational implementation study, not a randomized trial, so results may be influenced by staff training and patient selection. The device may not reduce contamination as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEVICE PERFORMANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEVICE PERFORMANCE EMERGENCY MEDICINE SEPSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Park City Hospital
RECRUITING

Park City, Utah, 84060, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.